Both medications cause some lean mass loss, but the ratio of fat loss to lean mass loss appears to favor tirzepatide based on available body composition data from the SURMOUNT trials
PMID: 38009416
The following study, incorporating data from six trials with 49,875 participants assessing four SGLT2 inhibitors, revealed a reduction in serious hyperkalemia risk (1754 cases) with a hazard ratio of 0.84 (95% CI, 0.76-0.93)
Recommended Significant Findings ViaLase Launches Clinical Trial for Incision-Free Glaucoma Procedure Josh Davidson, OD, FSLS, FAAOJosh Davidson, OD, FSLS, FAAO Significant Findings New Data Reveal Diabetes Affects Corneal Thickness Josh Davidson, OD, FSLS, FAAOJosh Davidson, OD, FSLS, FAAO Significant Findings Researchers Tackle AMD with Hyperthermia Josh Davidson, OD, FSLS, FAAOJosh Davidson, OD, FSLS, FAAO